|
1-5 (of 5) related articles
Items per page
| |
|
1. SHIRE SIGNS DEAL WITH SAMARITAN TO LAUNCH REPAGAL FOR FABRY.
Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, has signed a second exclusive marketing and distribution agreement, with Shire Human Genetic Therapies AB to ... (PREMIUM PERIODICAL ARTICLE)
2. DRAXIS GETS ACCEPTABLITY AFTER INSPECTON OF MANUFACTURING.
DRAXIS Health Inc. (TSX: DAX) (NASDAQ: DRAX), Mississauga, Ont., has received notification from the US Food and Drug Administration (FDA) that the company's manufacturing operations ... (PREMIUM PERIODICAL ARTICLE)
3. MIRCERA GETS POSITIVE OPINION IN EUROPE FOR ANAEMIA.
Roche, Basel, Switzerland, has received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) recommending a marketing authorization be granted ... (PREMIUM PERIODICAL ARTICLE)
4. S*BIO/UNIVERSITY OF SINGAPORE PARTNER ON TUMOR BIOAMARKER.
S*BIO Pte Ltd, a privately held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of ... (PREMIUM PERIODICAL ARTICLE)
5. ONCOLYTICS BIOTECH GETS 21ST U.S. PATENT.
Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), Calgary has been granted U.S. Patent 7,223,585 entitled "Viral Purification Methods." The claims cover the production and purification ... (PREMIUM PERIODICAL ARTICLE) | |
|
1-5 (of 5) related articles
Items per page
1-5 (of 5) related articles
|